Drug intelligence / Profile preview

indium In 111 adenosylcobalamin

Development stage
Unknown
Lead developer
Mayo Clinic
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

[111In]AC is a radiopharmaceutical diagnostic imaging agent composed of adenosylcobalamin (a form of Vitamin B12) conjugated to a chelator, typically diethylenetriaminepentaacetic acid (DTPA), and labeled with the gamma-emitting radioisotope indium-111. It is utilized in nuclear medicine, specifically Single Photon Emission Computed Tomography (SPECT) imaging, to visualize tumors that exhibit high rates of vitamin B12 uptake. Malignant cells, including those in breast cancer, often overexpress the transcobalamin receptor (CD320) to meet the increased metabolic demands of rapid proliferation and DNA synthesis. By mimicking the natural ligand, [111In]AC binds to the transcobalamin-receptor complex and is internalized via endocytosis, allowing for the non-invasive localization and characterization of primary and metastatic lesions.

Other names
indium-111 adenosylcobalaminindium111 adenosylcobalaminindium 111 adenosylcobalamin111In-adenosylcobalaminindium In 111 DTPA-adenosylcobalamin
02

Targets

CD320 (Transcobalamin II receptor)

Beyond the preview

Go deeper on indium In 111 adenosylcobalamin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on indium In 111 adenosylcobalamin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call